Kanadevia Corporation (TYO:7004)

Inozyme Pharma Revenue

Kanadevia had revenue of 125.44B JPY in the quarter ending June 30, 2025, with 3.19% growth. This brings the company's revenue in the last twelve months to 614.40B, up 6.86% year-over-year. In the fiscal year ending March 31, 2025, Kanadevia had annual revenue of 610.52B with 9.84% growth.

• Revenue (ttm): 614.40B
• Revenue Growth: +6.86%
• P/S Ratio: 0.28
• Revenue / Employee: 47.39M
• Employees: 12,964
• Market Cap: 171.58B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	610.52B	54.68B	9.84%
Mar 31, 2024	555.84B	63.15B	12.82%
Mar 31, 2023	492.69B	50.90B	11.52%
Mar 31, 2022	441.80B	33.21B	8.13%
Mar 31, 2021	408.59B	6.14B	1.53%